The babies suddenly stop breathing, after their airways collapse due to severe tracheobronchomalacia. One of every 2,200 children born suffers from this condition.
Conventional treatments for this condition are limited and often lead to life threatening complications. The patient needs to undergo hospitalization for tracheostomy along with a mechanical ventilation system. The above treatment can lead to cardiac and respiratory arrest.
The three babies aged 3 months, 16 months and 5 months were suffering from this condition.
No compilations were noted after they have fixed the 3D printed growth flexible implants in the babies.
The new technology can lead to better treatment of the Pediatric tracheobronchomalacia or TBM.
This condition leads to collapse of airways while breathing and can cause life threatening cardiopulmonary arrests. The cartilage which supports the airways can strengthen as the child grows but in severe cases it requires treatment and the new technology is like a wonder.
Babies suffering from TBM had to be hospitalized for tracheostomy tube placement with mechanical ventilation and the rate of respiratory arrest owing to tube occlusion is as high as 43 percent of pediatric tracheostomy procedures a year.
The 3D printed stents are flexible with the airway growth while preventing external compression over a period of time.
So the first few months are crucial for the survival of the babies. If the child can be supported through first 24 to 36 months of tracheobronchomalacia, airway growth will result in natural resolution of this disease.
“Before this procedure, babies with severe tracheobronchomalacia had little chance of surviving. Today, our first patient Kaiba is an active, healthy 3-year-old in preschool with a bright future. The device worked better than we could have ever imagined. We have been able to successfully replicate this procedure and have been watching patients closely to see whether the device is doing what it was intended to do. We found that this treatment continues to prove to be a promising option for children facing this life-threatening condition that has no cure,” said Dr. Glenn Green, associate professor of pediatric otolaryngology at C.S. Mott and senior author of the study.